$AGIO
AGIOS PHARMACEUTICALS, INC. Stock $agio

$agio Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000119312514192411 Filed on May 09, 2014

Income Statement

Concept	2014 Q2	2014 Q1	2013 Q1
Revenue	$8.411M	$8.411M	$6.268M
YoY Change	34.19%	34.19%	0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.170M	$3.290M	$1.850M
YoY Change	126.63%	77.84%	-6.57%
% of Gross Profit
Research & Development	$22.58M	$17.41M	$11.46M
YoY Change	74.22%	51.87%	20.02%
% of Gross Profit
Depreciation & Amortization	$400.0K	$332.0K	$349.0K
YoY Change	0.0%	-4.87%	16.33%
% of Gross Profit
Operating Expenses	$26.74M	$20.70M	$13.31M
YoY Change	80.76%	55.44%	15.47%
Operating Profit	-$18.33M	-$12.28M	-$7.046M
YoY Change	114.99%	74.34%	33.85%
Interest Expense	$30.00K	$40.00K	$10.00K
YoY Change	200.0%	300.0%	-66.67%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$18.30M	-$12.25M	-$7.038M
YoY Change	114.72%	74.03%	34.31%
Income Tax	$0.00	$0.00	$190.0K
% Of Pretax Income
Net Earnings	-$18.30M	-$12.25M	-$7.228M
YoY Change	112.25%	69.45%	56.08%
Net Earnings / Revenue	-217.52%	-145.62%	-115.32%
Basic Earnings Per Share	-$0.54	-$0.39
Diluted Earnings Per Share	-$0.54	-$0.39	-$1.949M
COMMON SHARES
Basic Shares Outstanding	33.96M shares	31.59M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q2	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$238.5M	$162.3M	$115.8M
YoY Change	140.16%	40.13%
Cash & Equivalents	$108.2M	$32.84M	$83.38M
Short-Term Investments	$130.2M	$129.4M	$32.40M
Other Short-Term Assets	$6.600M	$7.500M	$2.600M
YoY Change	106.25%	188.46%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$245.2M	$172.4M	$118.3M
YoY Change	139.11%	45.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.210M	$3.452M	$4.100M
YoY Change	-15.92%	-15.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$22.60M	$5.000M
YoY Change
Other Assets	$455.0K	$467.0K	$3.400M
YoY Change	-71.98%	-86.26%
Total Long-Term Assets	$26.87M	$9.495M	$7.600M
YoY Change	208.14%	24.93%
TOTAL ASSETS
Total Short-Term Assets	$245.2M	$172.4M	$118.3M
Total Long-Term Assets	$26.87M	$9.495M	$7.600M
Total Assets	$272.0M	$181.9M	$125.9M
YoY Change	144.52%	44.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.388M	$4.411M	$4.700M
YoY Change	77.35%	-6.15%
Accrued Expenses	$5.456M	$3.841M	$2.000M
YoY Change	52.15%	92.05%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$44.64M	$34.08M	$37.00M
YoY Change	20.71%	-7.89%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.000K	$3.000K	$51.70M
YoY Change	-100.0%	-99.99%
Total Long-Term Liabilities	$2.000K	$3.000K	$51.70M
YoY Change	-100.0%	-99.99%
TOTAL LIABILITIES
Total Short-Term Liabilities	$44.64M	$34.08M	$37.00M
Total Long-Term Liabilities	$2.000K	$3.000K	$51.70M
Total Liabilities	$44.64M	$34.08M	$88.70M
YoY Change	-45.83%	-61.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$144.0M	-$125.7M
YoY Change	60.19%
Common Stock	$344.5M	$247.0M
YoY Change	12031.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$200.5M	$121.3M	$37.10M
YoY Change
Total Liabilities & Shareholders Equity	$272.0M	$181.9M	$125.9M
YoY Change	144.52%	44.49%

Cashflow Statement

Concept	2014 Q2	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$18.30M	-$12.25M	-$7.228M
YoY Change	112.25%	69.45%	56.08%
Depreciation, Depletion And Amortization	$400.0K	$332.0K	$349.0K
YoY Change	0.0%	-4.87%	16.33%
Cash From Operating Activities	-$1.100M	-$27.00M	-$12.00M
YoY Change	-93.04%	125.0%	-25.0%
INVESTING ACTIVITIES
Capital Expenditures	-$100.0K	$13.00K	$275.0K
YoY Change	-85.71%	-95.27%
Acquisitions
YoY Change
Other Investing Activities	-$18.50M	-$12.30M	$4.300M
YoY Change	-274.53%	-386.05%	-58.65%
Cash From Investing Activities	-$18.60M	-$12.30M	$4.000M
YoY Change	-287.88%	-407.5%	-61.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	95.10M	600.0K	0.000
YoY Change	95000.0%
NET CHANGE
Cash From Operating Activities	-1.100M	-27.00M	-12.00M
Cash From Investing Activities	-18.60M	-12.30M	4.000M
Cash From Financing Activities	95.10M	600.0K	0.000
Net Change In Cash	75.40M	-38.70M	-8.000M
YoY Change	-1400.0%	383.75%	42.86%
FREE CASH FLOW
Cash From Operating Activities	-$1.100M	-$27.00M	-$12.00M
Capital Expenditures	-$100.0K	$13.00K	$275.0K
Free Cash Flow	-$1.000M	-$27.01M	-$12.28M
YoY Change	-93.38%	120.07%	-23.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33955643	shares
CY2010Q2	agio	Discover Period Under Collaboration Agreement DiscoverPeriodUnderCollaborationAgreement	P2Y
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	83377000
CY2013Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	0
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31832103	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1694284	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31832103	shares
CY2014Q1	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	30	Securities
CY2014Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.61
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3958495	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.84
CY2014Q1	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	0	Securities
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3272772	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.91
CY2013Q3	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	19731564	shares
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	0	Securities
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q1	us-gaap	Preferred Stock Value PreferredStockValue
CY2014Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3841000
CY2014Q1	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	1500000
CY2014Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	460000
CY2014Q1	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4411000
CY2014Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	667000
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	34081000
CY2014Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2014Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1436000
CY2014Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3000
CY2014Q1	us-gaap	Income Tax Examination Increase Decrease In Liability From Prior Year IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear	700000
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	121343000
CY2014Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	246970000
CY2014Q1	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	33000
CY2014Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-125692000
CY2014Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	25072000
CY2014Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	186000
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	32000
CY2014Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	133000
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	181912000
CY2014Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	624000
CY2014Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	26299000
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q1	us-gaap	Assets Current AssetsCurrent	172417000
CY2014Q1	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	5005000
CY2014Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	134404000
CY2014Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	4496000
CY2014Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	571000
CY2014Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	467000
CY2014Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	129432000
CY2014Q1	us-gaap	Assets Assets	181912000
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	99185000
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32837000
CY2014Q1	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	2619000
CY2014Q1	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	64791000
CY2014Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	134437000
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3033000
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.14
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3846168	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	116943000
CY2014Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	0
CY2014Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	17000000
CY2014Q1	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3452000
CY2014Q1	agio	Employee Stock Purchase Plan Shares Reserve For Future Issuance EmployeeStockPurchasePlanSharesReserveForFutureIssuance	327272	shares
CY2014Q1	agio	Available For Sale Debt Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestments	38000
CY2014Q1	agio	Available For Sale Debt Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleDebtSecuritiesGrossUnrealizedLossAccumulatedInInvestments	5000
CY2014Q1	agio	Potential Milestone Payment Receivable Upon Early Clinical Development Milestone Event PotentialMilestonePaymentReceivableUponEarlyClinicalDevelopmentMilestoneEvent	22500000
CY2014Q1	agio	One Time Receivable Eligibility Upon Dosing Of Last Patient Under First Split Licensed Program OneTimeReceivableEligibilityUponDosingOfLastPatientUnderFirstSplitLicensedProgram	25000000
CY2014Q1	agio	Accrued Contracted Research And Development Costs Current AccruedContractedResearchAndDevelopmentCostsCurrent	1278000
CY2011Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10700000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	91297000
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31202542	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31202542	shares
CY2013Q4	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	33	Securities
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6586000
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	140000
CY2013Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3678000
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	320000
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	36930000
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3642000
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6000
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	131482000
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	244881000
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	14000
CY2013Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-113444000
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	25072000
CY2013Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	220000
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	31000
CY2013Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	123000
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	201205000
CY2013Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1462000
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9000
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	32567000
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q4	us-gaap	Assets Current AssetsCurrent	169747000
CY2013Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	27125000
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	122320000
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	571000
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4000
CY2013Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	95209000
CY2013Q4	us-gaap	Assets Assets	201205000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71560000
CY2013Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	476000
CY2013Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	122334000
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2502000
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	76186000
CY2013Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	31700000
CY2013Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3758000
CY2013Q4	agio	Available For Sale Debt Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestments	20000
CY2013Q4	agio	Available For Sale Debt Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleDebtSecuritiesGrossUnrealizedLossAccumulatedInInvestments	6000
CY2010Q2	agio	Research Collaborative Arrangement Expiration Period ResearchCollaborativeArrangementExpirationPeriod	2014-04
CY2010Q2	agio	Agreement Amended Period AgreementAmendedPeriod	2011-10
CY2013Q4	agio	Unbilled Contracts Receivable From Related Party UnbilledContractsReceivableFromRelatedParty	476000
CY2013Q4	agio	Accrued Contracted Research And Development Costs Current AccruedContractedResearchAndDevelopmentCostsCurrent	2484000
CY2011Q4	agio	Initial Agreement Period InitialAgreementPeriod	P3Y
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2011Q4	agio	Extended Agreement Period ExtendedAgreementPeriod	P4Y
CY2011Q4	agio	Receipt Due To Agreement Amendment ReceiptDueToAgreementAmendment	20000000
CY2013Q4	agio	Initial Agreement Period InitialAgreementPeriod	P4Y
CY2013Q4	agio	Date Of Extension Of Discovery Phase DateOfExtensionOfDiscoveryPhase	2016-04
CY2013Q4	agio	Research Collaborative Arrangement Expiration Period ResearchCollaborativeArrangementExpirationPeriod	2015-04
CY2013Q4	agio	Extended Agreement Period ExtendedAgreementPeriod	P5Y
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y5M5D
CY2013	agio	Initial Agreement Period InitialAgreementPeriod	P4Y
CY2013	agio	Research Collaborative Arrangement Expiration Period ResearchCollaborativeArrangementExpirationPeriod	2015-04
CY2013	agio	Extended Agreement Period ExtendedAgreementPeriod	P5Y
CY2013	agio	Revenue Recognized On Extended Agreement RevenueRecognizedOnExtendedAgreement	500000
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate		pure
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate		pure
CY2013Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3658016	shares
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-11981000
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.87
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.47
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22931534	shares
CY2013Q1	us-gaap	Revenues Revenues	6300000
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	544000
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7229000
CY2013Q1	us-gaap	Contracts Revenue ContractsRevenue	6268000
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7038000
CY2013Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	15915000
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9025000
CY2013Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	8000
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7046000
CY2013Q1	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0
CY2013Q1	us-gaap	Straight Line Rent StraightLineRent	15000
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-7228000
CY2013Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	5000
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	275000
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000
CY2013Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	301000
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1852000
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	25000
CY2013Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-6268000
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	424000
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-7920000
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	4036000
CY2014Q1	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	20695000
CY2013Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	176000
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	829000
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11462000
CY2013Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	25000
CY2013Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	190000
CY2013Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	20226000
CY2013Q1	us-gaap	Depreciation Depreciation	349000
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	424000
CY2013Q1	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	190000
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	13314000
CY2013Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1797000
CY2013Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	190000
CY2013Q1	agio	Vesting Of Restricted Stock Value VestingOfRestrictedStockValue	16000
CY2014Q1	dei	Trading Symbol TradingSymbol	AGIO
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	AGIOS PHARMACEUTICALS INC
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001439222
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0182	pure
CY2014Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-5958000
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-27040000
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	21.81
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8418	pure
CY2014Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-2.75
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.34
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M6D
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y29D
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	31394563	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	30.42
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	720000
CY2014Q1	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17407000
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.93
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	746609	shares
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y2M27D
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y7M10D
CY2014Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	625016	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	9266	shares
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3977245	shares
CY2014Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.3636	pure
CY2014Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	582000
CY2014Q1	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit
CY2014Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit
CY2014Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	22560000
CY2014Q1	us-gaap	Depreciation Depreciation	332000
CY2014Q1	us-gaap	Revenues Revenues	8400000
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	930000
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12229000
CY2014Q1	us-gaap	Contracts Revenue ContractsRevenue	8411000
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12248000
CY2014Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	34812000
CY2014Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	13000
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12248000
CY2014Q1	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	121200000
CY2014Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	5958000
CY2014Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	36000
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-12284000
CY2014Q1	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0
CY2014Q1	us-gaap	Straight Line Rent StraightLineRent	24000
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-12248000
CY2014Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-168000
CY2014Q1	us-gaap	Royalty Revenue RoyaltyRevenue	0
CY2014Q1	us-gaap	Revenue Recognition Multiple Deliverable Arrangements Determination Of Selling Price Amount RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount	124300000
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13000
CY2014Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	19000
CY2014Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2194000
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3288000
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	582000
CY2014Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-6268000
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	24100000
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1505000
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-38723000
CY2014Q1	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-12265000
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1505000
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2014Q1	agio	Estimated Performance Period Of Agreement EstimatedPerformancePeriodOfAgreement	P6Y
CY2014Q1	agio	Vesting Of Restricted Stock Value VestingOfRestrictedStockValue	3000
CY2014Q1	agio	Number Of Vendors Selling Similar Competitive Products NumberOfVendorsSellingSimilarCompetitiveProducts	0	Vendor
CY2014Q1	agio	Number Of Licensed Programs Type Under Collaboration Agreements NumberOfLicensedProgramsTypeUnderCollaborationAgreements	3	Licensed_Program
CY2014Q1	agio	Period Considered For Agreement Termination Notice PeriodConsideredForAgreementTerminationNotice	P30D
CY2014Q1	agio	Tax Refund Due To Carry Back Of Losses TaxRefundDueToCarryBackOfLosses	3800000
CY2014Q1	agio	Number Of Development Candidates Nominated By Joint Research Committee NumberOfDevelopmentCandidatesNominatedByJointResearchCommittee	2	Candidate
CY2014Q1	agio	Accrued Initial Public Offering Stock Issuance Cost AccruedInitialPublicOfferingStockIssuanceCost	65000
CY2014Q1	agio	Increase Decrease In Unbilled Collaboration Revenue IncreaseDecreaseInUnbilledCollaborationRevenue	2143000
CY2014Q1	agio	Revenue Recognized On Extended Agreement RevenueRecognizedOnExtendedAgreement	2100000

Files In Submission

Name	View Source	Status
0001193125-14-192411-index-headers.html	Edgar Link	pending
0001193125-14-192411-index.html	Edgar Link	pending
0001193125-14-192411.txt	Edgar Link	pending
0001193125-14-192411-xbrl.zip	Edgar Link	pending
agio-20140331.xml	Edgar Link	completed
agio-20140331.xsd	Edgar Link	pending
agio-20140331_cal.xml	Edgar Link	unprocessable
agio-20140331_def.xml	Edgar Link	unprocessable
agio-20140331_lab.xml	Edgar Link	unprocessable
agio-20140331_pre.xml	Edgar Link	unprocessable
d705482d10q.htm	Edgar Link	pending
d705482dex311.htm	Edgar Link	pending
d705482dex312.htm	Edgar Link	pending
d705482dex321.htm	Edgar Link	pending
d705482dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AGIO
AGIOS PHARMACEUTICALS, INC. Stock $agio

2014 Q2 Form 10-Q Financial Statement

#000119312514192411 Filed on May 09, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGIO AGIOS PHARMACEUTICALS, INC. Stock $agio

2014 Q2 Form 10-Q Financial Statement

#000119312514192411 Filed on May 09, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGIO
AGIOS PHARMACEUTICALS, INC. Stock $agio